NYPOZI
Growthfilgrastim-txid
BLAINJECTIONINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NYPOZI (filgrastim-txid) is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. First approved in 2024.
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYPOZI (filgrastim-txid) is a granulocyte colony-stimulating factor (G-CSF) biologic that stimulates neutrophil proliferation and differentiation in bone marrow. It is administered by injection to patients requiring neutrophil support, such as those undergoing chemotherapy or with certain hematologic conditions. The drug works by binding to cell surface receptors on hematopoietic cells, enhancing neutrophil production, function, and survival.
Growth
Recent 2024 approval positions this as an emerging growth product with moderate competitive pressure (30/100), likely attracting early-stage commercial team expansion.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NYPOZI is a newly approved growth-stage biologic in a competitive but stable market, offering careers in brand management, sales, and access roles. Early-stage professionals can expect roles focused on market penetration, payer negotiation, and patient education rather than clinical development.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.